FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder
For Immediate Release: May 24, 2023 Today, the U.S. Food and Drug Administration (FDA) approved the extended-release Brixadi (buprenorphine) subcutaneous (for use under the skin) injection to treat moderate to severe opioid use disorder...